Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-FORCE: Ingrezza in Pediatric Tourette Syndrome
NCT02256475Phase 1Completed
- Sponsor
- Neurocrine Biosciences
- Start
- Sep 2014
- Primary completion
- Nov 2015
- Modality
- Orthosteric Ligands, Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of valbenazine in Tourette syndrome (TS) (6 arms), sponsored by Neurocrine Biosciences. Primary endpoints: Number of participants with adverse events up to 21 days, Area Under Curve of NBI-98854 and its metabolites at Day 14 and 1 more. Started Sep 2014; status: completed.
02
Drugs
valbenazine
03
Conditions
Tourette syndrome (TS)
Beyond the preview
Go deeper on NCT02256475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02256475.